Dr. Gadgeel on Pembrolizumab/Chemo Combo in NSCLC

Shirish Gadgeel, MD
Published: Tuesday, Aug 23, 2016



Shirish Gadgeel, MD, medical oncologist, leader of the Thoracic Oncology Multidisciplinary Team at Karmanos Cancer Institute, Wayne State University, discusses the KEYNOTE-021 study, which is examining the combination of pembrolizumab (Keytruda) and chemotherapy as a potential treatment for patients with non–small cell lung cancer (NSCLC).

In this phase I multicenter trial, pembrolizumab was combined with 3 cytotoxic chemotherapy regimens. Recently, findings from the first 3 cohorts were presented. Cohort A was comprised of pembrolizumab in combination with carboplatin/paclitaxel, while cohort B was pembrolizumab plus carboplatin/paclitaxel/bevacizumab (Avastin). Cohort C was pembrolizumab added to carboplatin/pemtrexed. Safety was the trial's primary endpoint.

Results showed that the combination was found to be fairly tolerable in all 3 cohorts, with approximately 25 patients in each arm. There was one case of a dose-limiting toxicity, Gadgeel adds. The overall response rate across 3 cohorts was 55%. The median progression-free survival was 10.5 months, and the median overall survival has not yet been observed.


Shirish Gadgeel, MD, medical oncologist, leader of the Thoracic Oncology Multidisciplinary Team at Karmanos Cancer Institute, Wayne State University, discusses the KEYNOTE-021 study, which is examining the combination of pembrolizumab (Keytruda) and chemotherapy as a potential treatment for patients with non–small cell lung cancer (NSCLC).

In this phase I multicenter trial, pembrolizumab was combined with 3 cytotoxic chemotherapy regimens. Recently, findings from the first 3 cohorts were presented. Cohort A was comprised of pembrolizumab in combination with carboplatin/paclitaxel, while cohort B was pembrolizumab plus carboplatin/paclitaxel/bevacizumab (Avastin). Cohort C was pembrolizumab added to carboplatin/pemtrexed. Safety was the trial's primary endpoint.

Results showed that the combination was found to be fairly tolerable in all 3 cohorts, with approximately 25 patients in each arm. There was one case of a dose-limiting toxicity, Gadgeel adds. The overall response rate across 3 cohorts was 55%. The median progression-free survival was 10.5 months, and the median overall survival has not yet been observed.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ALK-Positive NSCLC: Emerging Strategies to Inform Sequencing, Optimize Outcomes, and Address Unmet Clinical Needs Along the Disease ContinuumAug 29, 20181.5
Community Practice Connections™: Oncogenic Tumor Board in Advanced NSCLC: Leveraging Actionable Mutations Along the Disease Continuum to Optimize Patient OutcomesAug 30, 20182.0
Publication Bottom Border
Border Publication
x